Pramodini Medicare Limited
Pramodini Medicare Limited is a technology-enabled diagnostic services company operating across radiology, clinical laboratory, and nuclear medicine segments, serving hospitals, PSUs, and medical colleges in India. The company is raising funds via an SME IPO on NSE SME with a price band of ₹110–₹118 per share.
Overview
About the Company
Pramodini Medicare Limited, established in 2000, is a diagnostic services company headquartered in Vijayawada, Andhra Pradesh. It delivers technology-driven diagnostic solutions spanning radiology (MRI, CT scan, X-ray, ultrasound, mammography, DEXA scan, interventional radiology), clinical laboratory services (haematology, microbiology, immunology, pathology, biochemistry), and nuclear medicine (PET-CT, SPECT, nuclear therapy). The company runs a 24×7 teleradiology unit and a processing laboratory from Vijayawada. It operates through four business models: public-private partnerships with government hospitals and medical colleges, private-private partnerships with private hospitals, strategic collaborations with PSU entities, and standalone diagnostic centres. As of August 4, 2026, it managed 16 diagnostic centres spread across seven states. The company had 161 permanent employees as of March 31, 2026.
Company Details
📋 Objects of Issue (Use of Proceeds)
- › Funding capital expenditure for the acquisition of medical equipment for both existing and proposed diagnostic centres, estimated at ₹45.15 crores.
- › Meeting general corporate purposes and pursuing unidentified inorganic acquisition opportunities.
✅ Strengths
- ✓ The company has built a strategic presence across multiple states in India, enabling geographic diversification and reduced dependence on any single market.
- ✓ Its diversified business models — including PPP, private partnerships, PSU collaborations, and standalone centres — reduce concentration risk and broaden revenue streams.
- ✓ Robust IT infrastructure underpins the company's technical capabilities, supporting efficient delivery of diagnostic services including a 24×7 teleradiology unit.
- ✓ The management team brings considerable expertise and experience in the healthcare diagnostics sector.
- ✓ The company has demonstrated a consistent upward trajectory in revenue and profitability across recent financial years.
- ✓ A diverse customer base comprising public hospitals, private hospitals, PSUs, medical colleges, and individual patients provides stable and recurring revenue.
⚠️ Risks
- ! As an SME IPO, the company may face limited liquidity in secondary market trading compared to mainboard-listed peers.
- ! Operations are concentrated in diagnostic centres across seven states; any adverse regulatory changes in those states or disruptions at key locations could impact performance.
- ! The company relies on long-term MOUs and contracts with government and private hospitals; non-renewal or renegotiation of such agreements could adversely affect revenues.
- ! Capital expenditure requirements for medical equipment are significant, and inability to procure or maintain advanced diagnostic equipment could hinder service quality and growth.
- ! A substantial portion of proceeds is earmarked for equipment purchases, and delays or cost overruns in capital deployment could affect expansion plans.
- ! The healthcare diagnostics sector is competitive, with several established players; failure to retain pricing power or differentiate services could compress margins.